Drug Access Listing

Tablet, PO

• 60mg 

• 240mg 

60mg: 02478374 

240mg: 02540185 

Criteria for initial 12-month coverage: For the treatment of non-metastatic castration-resistant prostate cancer patients (nmCRPC) who meet all the following criteria: 

• used in combination with androgen deprivation therapy (ADT); and  

• have no detectable distant metastases by either CT, MRI or technetium-99m bone scan; and 

• are at high risk* of developing metastases; and 

• have no risk factors for seizures; and - have a good Eastern Cooperative Oncology Group status (ECOG) performance status (0 or 1).  

* high risk is defined as a prostate-specific antigen doubling time of <= 10 months during continuous ADT.  

Criteria for renewal every 12 months: There is no objective evidence of radiographic disease progression or unacceptable toxicity. 

NIHB Drug Benefit List 

Janssen (Janssen BioAdvance Patient Assistance Program):  

https://www.bioadvancemember.ca/s/reimbursement-support?language=en_US

Tablet, PO

• 60mg 

• 240mg 

60mg: 02478374 

240mg: 02540185 

Criteria for initial 12-month coverage: For the treatment of metastatic castration-sensitive prostate cancer patients (mCSPC) who meet all the following criteria: 

• used in combination with androgen deprivation therapy (ADT); and 

• patient is castration sensitive (i.e., no prior ADT or within six months of beginning ADT); and 

• have a good ECOG performance status (0 or 1). 

Criteria for renewal every 12 months: There is no objective evidence of radiographic disease progression or unacceptable toxicity.

NIHB Drug Benefit List 

Janssen (Janssen BioAdvance Patient Assistance Program):  

https://www.bioadvancemember.ca/s/reimbursement-support?language=en_US

45 mg / 4.5 mL

02487497

Website update in progress. Please refer to provincial formulary for more information.

-

-

60 mg / Syr Injection 

02545411 

Pending 

Sandoz Plus PSP 

Sandoz Plus | My Sandoz Patients 

Jubbonti 

Inj. Sol.  
120 mg /1.7mL 

02545764 

Pending  

Sandoz Plus PSP 

Sandoz Plus | My Sandoz Patients 

7.5mg-30mg mg / Syr Injection 

3.75mg = 00884502,

7.5mg = 00836273,

11.25mg = 02239834,

22.5mg = 02230248,

30mg = 02239833 

Public benefit 

Haven: 

Drug Access Canada - Haven by Sentrex 

100 mg tab | 150 mg tab

100mg: 02475200 | 150mg: 02475219

Funded as per NIHB criteria: 

• Criteria for initial 12-month coverage: 

• For the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC); and  

• Olaparib is used as monotherapy; and 

• Patient has good performance status; and 

• Patient has progressed following prior treatment with a new hormonal agent/androgen-receptor-axis-targeted therapy (ARAT); and 

• Patient has deleterious or suspected deleterious mutations (germline or somatic) in the homologous recombination repair (HRR) genes BRCA or ATM. 

NIHB Drug Benefit List 

AstraZeneca Patient Support Program: Access Here

AstraZeneca Patient Assistance Program: Access Here

120 mg tablet

02542137

Listed as an open benefit through the NIHB program.

NIHB Drug Benefit List

Copay cards available from manufacturer

0.1 mg, 0.25 mg, 0.35 mg, 0.5 mg and 1 mg

02492032
02492040

Website update in progress. Please refer to provincial formulary for more information.

-

-